Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4705 Comments
893 Likes
1
Jhovani
Loyal User
2 hours ago
That deserves a meme. π
π 204
Reply
2
Pascal
New Visitor
5 hours ago
Who else is still figuring this out?
π 51
Reply
3
Carmia
Engaged Reader
1 day ago
I hate realizing things after itβs too late.
π 71
Reply
4
Makenah
Experienced Member
1 day ago
I read this and forgot what I was doing.
π 132
Reply
5
Daxyn
Active Reader
2 days ago
Free US stock market sentiment analysis and institutional activity tracking to understand what smart money is doing in the market. Our tools reveal buying and selling patterns of large institutional investors who often move stock prices significantly. We provide 13F filing analysis, options flow data, and sector rotation indicators for comprehensive market intelligence. Follow the money and make smarter investment decisions with our comprehensive sentiment analysis and institutional tracking tools.
π 113
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.